NIH

Vanderbilt investigators have constructed a network map that could guide the development of new targeted cancer therapies. Read More

A new brain study has identified the brain mechanisms that underlie our judgment of how severely a person who has harmed another should be punished. Read More

Vanderbilt researchers have discovered that the protein CRADD counteracts inflammatory injury to endothelial cells, which could assist the development of new therapies for inflammatory vascular disorders. Read More

The protein MTBP is overexpressed in an aggressive type of breast cancer, and it regulates another protein implicated in many cancer types, suggesting that it may be a good target for new therapeutics. Read More

Understanding how the immune system responds to the respiratory virus HMPV is crucial for developing vaccines and anti-viral treatments. Read More

Augmenting the signals of natural “endocannabinoids” in the brain may be a promising approach for treating mood and anxiety disorders. Read More

A newly identified receptor allows mammalian reovirus to infect neurons, shedding light on factors important for viral encephalitis. Read More

Understanding how to control the generation of regulatory T cells could have important implications for treating autoimmunity and cancer. Read More

A novel molecular “conversation” regulates kidney fibrosis – the final result of end-stage chronic kidney disease – suggesting new treatment options for this currently irreversible process. Read More

Vanderbilt researcher Bernard Rousseau, Ph.D., is being appointed to the Motor Function, Speech and Rehabilitation Study Section at the Center for Scientific Review, National Institutes of Health, for the term beginning July 1 and ending June 30, 2020. Read More